Angling for a greater haul in the bullish market for biotech products, diversified medtech firm Thermo Fisher Scientific (NYSE: TMO) is to buy Netherlands-incorporated Patheon (NYSE: PTHN), a contract manufacturing organization.
Thermo Fisher will commence a tender offer to buy up shares in the company, which provides comprehensive biopharmaceutical development services, for around $7.2 billion, including $2 billion of net debt.
Patheon has developed into one of the world’s largest CMOs through a series of mergers and acquisitions, including a $2.65 billion deal with the pharmaceutical products business of Royal DSM (Euronext: DSM KON) in 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze